Showing results (51-60 of 649) with videos related to
Sort By:
Pageof 65
Nature Cancer|February 5, 2022
IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapyAdi Jacob Berger, Elinor Gigi, Lana Kupershmidt, et al.Nature Cancer|February 5, 2022
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.Nature Cancer|February 5, 2022
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastomaVíctor A Arrieta, Andrew X Chen, J Robert Kane, et al.Nature Cancer|February 5, 2022
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44Amy L Cummings, Jaklin Gukasyan, Henry Y Lu, et al.Nature Cancer|February 5, 2022
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.Nature Cancer|February 5, 2022
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapesErin Pleasance, Emma Titmuss, Laura Williamson, et al.Nature Cancer|February 5, 2022
Zeb2 drives invasive and microbiota-dependent colon carcinomaKarolina Slowicka, Ioanna Petta, Gillian Blancke, et al.Nature Cancer|February 5, 2022
Genomics-guided pre-clinical development of cancer therapiesHayley E Francies, Ultan McDermott, Mathew J GarnettNature Cancer|February 5, 2022
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancerBaolin Liu, Xueda Hu, Kaichao Feng, et al.Nature Cancer|February 5, 2022
The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancerJiang Liu, Liyan Lao, Jianing Chen, et al.Pageof 65